Rani Therapeutics Holdings, Inc.
- Last sale
- Nov 6, 2026 · +5.24%
- Market cap
- $75.56M
- 139.46M shares
- Filings
- 384
Q3 2026+58.9% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+394.9% FY25 yoy
- $75.56M
- —
- 11.5×
- 2.2×
- -30.73%
- —
Twelve months to Sep 30, 2026 · derived
Price
Nov 6, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $1,633,000 | reported | |
| FY 2024 | 2024-12-31 | $1,028,000 | reported | |
| FY 2023 | 2023-12-31 | $0 | reported | |
| FY 2022 | 2022-12-31 | $0 | reported | |
| FY 2021 | 2021-12-31 | $2,717,000 | reported | |
| FY 2020 | 2020-12-31 | $462,000 | reported |
Pharmaceutical preparations
Rani Therapeutics Holdings, Inc. is the 205th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
KRSAKorsana Biosciences, Inc.$2.1M3.7%170.1%$1.4BDNTHDianthus Therapeutics, Inc.$2.0M67.3%7,973.3%$5.2BORMPOramed Pharmaceuticals Inc.$2.0M—3,202.5%$175.2MLPCNLipocine Inc.$2.0M82.3%487.1%$17.9MBIOEBio Essence Corp$1.9M485.8%47.2%$19.0M
RANIRani Therapeutics Holdings, Inc. (this company)$1.6M58.9%1,817.1%$75.6M
ATXIAvenue Therapeutics, Inc.$1.4M—207.2%$988.5KNWBONorthwest Biotherapeutics Inc$1.4M0.3%4,365.9%$272.9MCPMDCannapharmarx, Inc.$1.4M66.1%817.2%$6.6MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Rani Therapeutics Holdings, Inc. · CIK 1856725 · Engraved from SEC EDGAR